T Martijn Kuijper1, Femke B G Lamers-Karnebeek2, Johannes W G Jacobs2, Johanna M W Hazes2, Jolanda J Luime2. 1. From the Department of Rheumatology, Erasmus Medical Center, Rotterdam; Department of Rheumatology, Radboud University Medical Center, Nijmegen; Department of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, the Netherlands.T.M. Kuijper, MD, MSc, Department of Rheumatology, Erasmus Medical Center; F.B. Lamers-Karnebeek, MD, Department of Rheumatology, Radboud University Medical Center; J.W. Jacobs, MD, PhD, Department of Rheumatology and Clinical Immunology, University Medical Center; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus Medical Center. t.kuijper@erasmusmc.nl. 2. From the Department of Rheumatology, Erasmus Medical Center, Rotterdam; Department of Rheumatology, Radboud University Medical Center, Nijmegen; Department of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, the Netherlands.T.M. Kuijper, MD, MSc, Department of Rheumatology, Erasmus Medical Center; F.B. Lamers-Karnebeek, MD, Department of Rheumatology, Radboud University Medical Center; J.W. Jacobs, MD, PhD, Department of Rheumatology and Clinical Immunology, University Medical Center; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus Medical Center.
Abstract
OBJECTIVE: To evaluate the risk of having a disease flare in patients with rheumatoid arthritis (RA) with low disease activity (LDA) or in remission when deescalating (tapering or stopping) disease-modifying antirheumatic drug (DMARD) therapy. METHODS: A search in medical databases including publications from January 1950 to February 2015 was performed. Included were trials and observational studies in adults with RA who were in LDA or remission, evaluating ≥ 20 patients tapering or stopping DMARD. Flare rates had to have been reported. A metaanalysis was performed on studies deescalating tumor necrosis factor (TNF) blockers. RESULTS: Four studies evaluated synthetic DMARD. Flare rates ranged from 8% at 24 weeks to 63% at 4 months after deescalation. Fifteen studies reported on TNF blockers. Estimated flare rates by metaanalysis on studies tapering or stopping TNF blockers were 0.26 (95% CI 0.17-0.39) and 0.49 (95% CI 0.27-0.73) for good-quality and moderate-quality studies, respectively. Flare rates in 3 studies stopping tocilizumab were 41% after 6 months, 55% at 1 year, and 87% at 1 year. Flare rates in 3 studies deescalating abatacept were 34% at 1 year, 41% at 1 year, and 72% at 6 months. Five studies evaluating radiographic progression in patients deescalating treatment all found limited to no progression. CONCLUSION: Results suggest that more than one-third of patients with RA with LDA or in remission may taper or stop DMARD treatment without experiencing a disease flare within the first year. Dose reduction of TNF blockers results in lower flare rates than stopping and may be noninferior to continuing full dose. Radiological progression after treatment deescalation remains low, but may increase slightly.
OBJECTIVE: To evaluate the risk of having a disease flare in patients with rheumatoid arthritis (RA) with low disease activity (LDA) or in remission when deescalating (tapering or stopping) disease-modifying antirheumatic drug (DMARD) therapy. METHODS: A search in medical databases including publications from January 1950 to February 2015 was performed. Included were trials and observational studies in adults with RA who were in LDA or remission, evaluating ≥ 20 patients tapering or stopping DMARD. Flare rates had to have been reported. A metaanalysis was performed on studies deescalating tumor necrosis factor (TNF) blockers. RESULTS: Four studies evaluated synthetic DMARD. Flare rates ranged from 8% at 24 weeks to 63% at 4 months after deescalation. Fifteen studies reported on TNF blockers. Estimated flare rates by metaanalysis on studies tapering or stopping TNF blockers were 0.26 (95% CI 0.17-0.39) and 0.49 (95% CI 0.27-0.73) for good-quality and moderate-quality studies, respectively. Flare rates in 3 studies stopping tocilizumab were 41% after 6 months, 55% at 1 year, and 87% at 1 year. Flare rates in 3 studies deescalating abatacept were 34% at 1 year, 41% at 1 year, and 72% at 6 months. Five studies evaluating radiographic progression in patients deescalating treatment all found limited to no progression. CONCLUSION: Results suggest that more than one-third of patients with RA with LDA or in remission may taper or stop DMARD treatment without experiencing a disease flare within the first year. Dose reduction of TNF blockers results in lower flare rates than stopping and may be noninferior to continuing full dose. Radiological progression after treatment deescalation remains low, but may increase slightly.
Authors: Susan J Bartlett; Skye P Barbic; Vivian P Bykerk; Ernest H Choy; Rieke Alten; Robin Christensen; Alfons den Broeder; Bruno Fautrel; Daniel E Furst; Francis Guillemin; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham Journal: J Rheumatol Date: 2017-08-15 Impact factor: 4.666
Authors: Anouk van Hooij; Debbie M Boeters; Elisa M Tjon Kon Fat; Susan J F van den Eeden; Paul L A M Corstjens; Annette H M van der Helm-van Mil; Annemieke Geluk Journal: Clin Vaccine Immunol Date: 2017-08-04
Authors: Kyle Hayes; Mary P Panaccio; Parul Houston; John Niewoehner; Mohammed Fahim; George J Wan; Bhavna Dhillon Journal: Open Access Rheumatol Date: 2021-10-15
Authors: Lise M Verhoef; Bart Jf van den Bemt; Aatke van der Maas; Johanna E Vriezekolk; Marlies E Hulscher; Frank Hj van den Hoogen; Wilco Ch Jacobs; Noortje van Herwaarden; Alfons A den Broeder Journal: Cochrane Database Syst Rev Date: 2019-05-24
Authors: Fowzia Ibrahim; Beatriz Lorente-Cánovas; Caroline J Doré; Ailsa Bosworth; Margaret H Ma; James B Galloway; Andrew P Cope; Ira Pande; David Walker; David L Scott Journal: Rheumatology (Oxford) Date: 2017-11-01 Impact factor: 7.580